Mastery Studying Ensures Right Private Protecting Gear Use in Simulated Medical Encounters of COVID-19
Introduction: The proper use of private protecting gear (PPE) limits transmission of significant communicable ailments to healthcare employees, which is critically necessary within the period of coronavirus illness 2019 (COVID-19). Nonetheless, prior research illustrated that healthcare employees often err throughout utility and elimination of PPE. The aim of this research was to find out whether or not a simulation-based, mastery studying intervention with deliberate observe improves appropriate use of PPE by physicians throughout a simulated medical encounter with a COVID-19 affected person.
Strategies:
This was a pretest-posttest research carried out within the emergency division at a big, educational tertiary care hospital between March 31-April 8, 2020. A complete of 117 topics participated, together with 56 school members and 61 resident physicians. Previous to the intervention, all contributors acquired institution-mandated training on PPE use by way of a web based video and supplemental supplies.
Individuals accomplished a pretest abilities evaluation utilizing a 21-item guidelines of steps to appropriately don and doff PPE. Individuals had been anticipated to fulfill a minimal passing rating (MPS) of 100%, decided by an skilled panel utilizing the Mastery Angoff and Affected person Security standard-setting strategies. Individuals that met the MPS on pretest had been exempt from the tutorial intervention.
Testing occurred earlier than and after an in-person demonstration of correct donning and doffing strategies and 20 minutes of deliberate observe. The first end result was a change in evaluation scores of appropriate PPE use following our instructional intervention. Secondary outcomes included variations in efficiency scores between school members and resident physicians, and variations in efficiency throughout donning vs doffing sequences.
Outcomes: All contributors had a imply pretest rating of 73.1% (95% confidence interval [CI], 70.9-75.3%). College member and resident pretest scores had been related (75.1% vs 71.3%, p = 0.082). Imply pretest doffing scores had been decrease than donning scores throughout all contributors (65.8% vs 82.8%, p<0.001). Participant scores elevated 26.9% (95% CI of the distinction 24.7-29.1%, p<0.001) following our instructional intervention leading to all contributors assembly the MPS of 100%.
Conclusion: A mastery studying intervention with deliberate observe ensured the proper use of PPE by doctor topics in a simulated medical encounter of a COVID-19 affected person. Additional research of translational outcomes is required.
Multiplex detection of ctDNA mutations in plasma of colorectal most cancers sufferers by PCR/SERS assay
Molecular diagnostic testing of KRAS and BRAF mutations has turn out to be crucial within the administration of colorectal most cancers (CRC) sufferers. Some progress has been made in liquid biopsy detection of mutations in circulating tumor DNA (ctDNA), which is a fraction of circulating cell-free DNA (cfDNA), however gradual evaluation for DNA sequencing strategies has restricted speedy diagnostics.
Different strategies reminiscent of quantitative PCR and extra lately, droplet digital PCR (ddPCR), have limitations in multiplexed capability and the necessity for costly specialised gear. Therefore, a sturdy, speedy and facile technique is required for detecting a number of ctDNA mutations to enhance the administration of CRC sufferers. To deal with this important drawback, herein, we suggest a brand new utility of multiplex PCR/SERS (surface-enhanced Raman scattering) assay for the detection of ctDNA in CRC, in a quick and non-invasive method to diagnose and stratify sufferers for efficient remedy.
Strategies: To discriminate ctDNA mutations from wild-type cfDNA, allele-specific primers had been designed for the amplification of three clinically necessary DNA level mutations in CRC together with KRAS G12V, KRAS G13D and BRAF V600E. Floor-enhanced Raman scattering (SERS) nanotags had been labelled with a brief and particular sequence of oligonucleotide, which may hybridize with the corresponding PCR amplicons. The PCR/SERS assay was applied by firstly amplifying the a number of mutations, adopted by binding with multicolor SERS nanotags particular to every mutation, and subsequent enrichment with magnetic beads. The mutation standing was evaluated utilizing a conveyable Raman spectrometer the place the fingerprint spectral peaks of the corresponding SERS nanotags point out the presence of the mutant targets. The tactic was then utilized to detect ctDNA from CRC sufferers beneath a blinded take a look at, the outcomes had been additional validated by ddPCR.
Outcomes: The PCR/SERS technique confirmed excessive specificity and sensitivity for genotyping CRC cell traces and plasma ctDNA, the place as few as 0.1% mutant alleles could possibly be detected from a background of plentiful wild-type cfDNA. The blinded take a look at utilizing 9 samples from superior CRC sufferers by PCR/SERS assay was validated with ddPCR and confirmed good consistency with pathology testing outcomes.
Conclusions: With ddPCR-like sensitivity but on the comfort of normal PCR, the proposed assay reveals nice potential in delicate detection of a number of ctDNA mutations for medical decision-making.
Immunogen information: Synthesized peptide derived from the C-terminal region of human D-GPCR at AA range: 210-290
Applications tips:
Description: A polyclonal antibody for detection of D-GPCR from Human. This D-GPCR antibody is for WB, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human D-GPCR at AA range: 210-290
Immunogen information: Synthesized peptide derived from the C-terminal region of human D-GPCR at AA range: 210-290
Applications tips:
Description: A polyclonal antibody for detection of D-GPCR from Human. This D-GPCR antibody is for WB, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human D-GPCR at AA range: 210-290
Immunogen information: Synthesized peptide derived from the C-terminal region of human D-GPCR at AA range: 210-290
Applications tips:
Description: A polyclonal antibody for detection of D-GPCR from Human. This D-GPCR antibody is for WB, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human D-GPCR at AA range: 210-290
Description: A wide range of well-characterized bioactive molecules that covers various targets related to GPCR, including adenosine receptor, adrenergic receptor and CXCR etc. Facilitate your research towards the insights of cancer, neurological disorders and heart diseases etc.
CORNING® LSE™ MINI MICROCENTRIFUGE 0.20 ADAPTER FOR 6770-RT
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012]
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC .
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP.
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE .
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin.
Medical interns’ reflections on their coaching in use of private protecting gear
Background: The present COVID-19 pandemic has demonstrated that non-public protecting gear (PPE) is crucial, to forestall the acquisition and transmission of infectious ailments, but its use is usually sub-optimal within the medical setting.
Coaching and training are necessary to make sure and maintain the secure and efficient use of PPE by medical interns, however present strategies are sometimes insufficient in offering the related data and abilities. The aim of this research was to discover medical graduates’ experiences of using PPE and determine alternatives for enchancment in training and coaching programmes, to enhance occupational and affected person security.
Strategies: This research was undertaken in 2018 in a big tertiary-care instructing hospital in Sydney, Australia, to discover medical interns’ self-reported experiences of PPE use, firstly of their internship. Reflexive teams had been performed instantly after theoretical and sensible PPE coaching, throughout hospital orientation. Transcripts of recorded discussions had been analysed, utilizing a thematic method that drew on the COM-B (functionality, alternative, motivation – behaviour) framework for behaviour.
Outcomes: 80% of 90 eligible graduates participated. Many interns had not beforehand acquired formal coaching within the particular abilities required for optimum PPE use and had developed probably unsafe habits. Their experiences as medical college students in medical areas contrasted sharply with advisable observe taught at hospital orientation and impacted on their potential to domesticate appropriate PPE use.
Conclusions: Undergraduate instructing must be according to finest observe PPE use, and embody sensible coaching that embeds appropriate and secure practices.
RTA 408 
RTA-408 )
Omaveloxolone (RTA-408) 
GPCR GPR86 Antibody 
GPCR RDC1 Antibody 
GPCR GPR86 Conjugated Antibody 
GPCR RDC1 Conjugated Antibody 
D-GPCR Polyclonal Antibody 
Anti-D-GPCR Antibody 
Anti-D-GPCR antibody 
Anti-GPCR GPR3 Antibody 
Anti-GPCR GPR40 Antibody 
anti-GPCR GPR3 
anti-GPCR GPR34 
anti-GPCR HM74 
anti-GPCR GPR146 
anti-GPCR MRGX2 
anti-GPCR LOC51210 
anti-GPCR 2037 
anti-GPCR GPR110 
anti-GPCR C5L2 
anti-GPCR SALPR 
anti-GPCR GPRC5D 
anti-GPCR EX33 
anti-GPCR LGR7 
anti-GPCR LGR6 
anti-GPCR TAS1R1 
anti-GPCR GPR62 
Anti-GPCR GPR40/FFAR1 Antibody 
Anti-GPCR LGR8/RXFP2 Antibody 
Anti-LGR6/Gpcr Lgr6 Antibody 
Anti-GPCR GPR7/NPBWR1 Antibody 
Anti-GPR151/Gpcr 2037 Antibody 
Anti-GPCR GPR3 Antibody BIOTIN 
Anti-GPCR GPR3 Antibody FITC 
Anti-GPCR GPR40 Antibody BIOTIN 
Anti-GPCR GPR40 Antibody FITC 
Human GPCR ELISA Kit 
Goat GPCR ELISA Kit 
Canine GPCR ELISA Kit 
Chicken GPCR ELISA Kit 
Bovine GPCR ELISA Kit 
Porcine GPCR ELISA Kit 
Rat GPCR ELISA Kit 
Rabbit GPCR ELISA Kit 
Sheep GPCR ELISA Kit 
Mouse GPCR ELISA Kit 
Monkey GPCR ELISA Kit 
DiscoveryProbe? GPCR Compound Library )
Anti-GPCR SALPR (1F10) )
Anti-GPCR EX33 (5C3) )
Anti-GPCR EX33 (5B7) )
Anti-GPCR EX33 (1D9) )
Anti-GPCR GPR48 (8F6) )
Anti-GPCR GPRC5D (6D9) )
Anti-GPCR LGR7 (3E3) )
Anti-GPCR LOC51210 (6D7) 
Guinea Pig GPCR ELISA Kit 
Anserini GPCR-APJ ELISA Kit 
anti-5-oxo-ETE GPCR )
Orphan GPCR SP9155 Agonist P518 (human) )
Orphan GPCR SP9155 Agonist P550 (mouse) 
DiscoveryProbe? GPCR/G protein-related Compounds Panel 
CORNING® LSE™ MINI MICROCENTRIFUGE 0.20 ADAPTER FOR 6770-RT 
CORNING® LSE™ MINI MICROCENTRIFUGE 0.25 ADAPTER FOR 6770-RT 
CORNING® LSE™ MINI MICROCENTRIFUGE 0.5 ADAPTER FOR 6770-RT 
H2B Antibody Antibody 
CD11b Antibody Antibody 
anti- Antibody^Polyclonal antibody control antibody  Antibody)
Ly1 Antibody Reactive (LYAR) Antibody  Antibody)
Anti-Glycolipid Antibody (AGA) Antibody  Antibody)
Anti-Glycoprotein Antibody (GP) Antibody 
Anti-Anti-SEPT2 Antibody antibody 
Anti-Anti-SEPT7 Antibody antibody 
Anti-Anti-SEPT6 antibody antibody 
Anti-Anti-SEPT5 Antibody antibody 
Anti-Anti-SEPT8 Antibody antibody 
Anti-Anti-SEPT9 Antibody antibody 
Anti-Anti-SEPT11 Antibody antibody 
Anti-Anti-SEPT4 Antibody antibody 
Anti-Anti-MARCH9 Antibody antibody 
Anti-Anti-MARCH8 Antibody antibody 
Anti-Anti-MARCH6 Antibody antibody 
Anti-Anti-MARCH7 Antibody antibody 
Anti-Anti-SEPT3 Antibody antibody 
Anti-Anti-SEPT1 antibody antibody 
Anti-Anti-SEPT12 Antibody antibody 
Monoclonal NGF/proNGF Neutralizing Antibody Antibody  Antibody)
Ly1 Antibody Reactive Homolog (LYAR) Antibody  Antibody)
Hepatitis C Virus Antibody (HCV) Antibody  Antibody (HRP))
Anti-Glycoprotein Antibody (GP) Antibody (HRP)  Antibody (FITC))
Anti-Glycoprotein Antibody (GP) Antibody (FITC)  Antibody (Biotin))
Anti-Glycoprotein Antibody (GP) Antibody (Biotin)  Antibody (HRP))
Ly1 Antibody Reactive (LYAR) Antibody (HRP)  Antibody (FITC))
Ly1 Antibody Reactive (LYAR) Antibody (FITC)  Antibody (Biotin))
Ly1 Antibody Reactive (LYAR) Antibody (Biotin)  Antibody)
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody  Antibody)
Anti-Glycoprotein 210 Antibody (gp210) Antibody 
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody 
Anti CD22 Antibody: CD22 Monoclonal Antibody 
Antibody Pair to ApoA-V antibody 
Goat anti- human Antibody^Polyclonal antibody 
Anti-Noelin Antibody BIOTIN Antibody BIOTIN 
Anti-Noelin Antibody FITC Antibody FITC 
Antibody for Human alpha Tubulin Antibody